Your session is about to expire
← Back to Search
Hormone Therapy
NTx 265 for Traumatic Brain Injury
Phase 2
Waitlist Available
Led By David A Zygun, MD, MSc
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
Study Summary
Prospective, Open Label, Cohort Study in Traumatic Brain Injury Patients. The goal of this study is to assess the safety of NTx®-265. NTx®-265 will be administered over 9 days, and patients will be followed for an additional 6 months.
Eligible Conditions
- Traumatic Brain Injury
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety
Secondary outcome measures
Efficacy
Trial Design
1Treatment groups
Experimental Treatment
Group I: NTx 265Experimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Stem Cell Therapeutics Corp.Industry Sponsor
4 Previous Clinical Trials
275 Total Patients Enrolled
University of CalgaryLead Sponsor
791 Previous Clinical Trials
868,724 Total Patients Enrolled
David A Zygun, MD, MScPrincipal InvestigatorUniversity of Calgary
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger